Abstract 279P
Background
The moderated hypofractionation (MoHF) radiotherapy (RT) protocols offer an alternative treatment (Tx) that solves both the workload issue as well as the duration of Tx for prostate cancer (PC) patients while delivering a more adapted dose to the tumor cells. Therefore, the MoHF protocol has been implemented in our department using the Volumetric Arc Modulated Therapy (VMAT) with Image Guided Radiation Therapy (IGRT) for our PC patients.
Methods
From May 24th 2021 to June 30th 2023, there were totally 23 patients who were applied the MoHF protocols. Initially, we implemented protocol of 60Gy in 20 fractions (60Gy/20fx) for intermediate-risk PC patients. Since December 2022, the protocol of 68Gy in 25 fractions (68Gy/25fx) was implemented for high-risk PC patients based on the new data of PCS5 trial. All patients were treated accordingly to institutional protocol for Tx of PC. A weekly consultation during RT course was also held for each patient to follow up with the possible acute side effects.
Results
The average duration to complete Tx planning was 7 days. For dose constraint achievement, 100% of planning had D2% < 107% of dose prescription while 21/23 plans (91.30%) achieved the criteria of planning target volum (PTV) coverage as well as organs at risk (OARs) protection. 2/23 plans (8.70%) were validated with a minor deviation in either target coverage or OARs constraints. The most common acute toxicity was dysuria which happened on 21/23 cases (91.30%) with grade 1 or 2. This side effect was resolutive in 100% of patients within 1 month after completion of Tx. No grade 3 or higher acute or late toxicity was reported. The cost-effectiveness of the MoHF protocols, was compared to a normo-fractionated protocol in 8 weeks (80Gy/40fx). The cost of RT was reduced by 25% going from more than 7000USD for the 8-weeks protocol to 5800USD for the 68Gy/25fx protocol and to 4900USD for the 60Gy/20fx protocol. The entire treatment costs were further reduced due to lower accommodation and transportation fees in the shorter protocols.
Conclusions
For PC patients indicated with definitive RT, the MoHF is a more convenient and safer alternative with manageable side effects and a reduction of treatment direct and indirect cost.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract